Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Negative regulation of p53 expression is an essential, rate-limiting function of Jun in the control of cell cycle progression

Authors: M Schreiber, F Piu, A Kolbus, A Szabowski, U Möhle-Steinlein, J Tian, M Karin, P Angel, EF Wagner

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

The tumor suppressor gene p53 is inactivated by mutations in >50% of human tumors, including breast cancers. Here we show that p53 expression is negatively regulated by the Jun proto-oncogene, which encodes a component of the mitogen-inducible immediate-early transcription factor AP-1 and has been implicated as a positive regulator of cell proliferation. In fibroblasts derived from Jun-/- mouse fetuses, the tumor suppressor gene p53 and its target gene, the CDK inhibitor p21, are expressed at elevated levels, whereas overexpression of Jun represses p53 and p21 expression. Surprisingly, protein stabilisation, the common mechanism of p53 regulation, does not seem to be involved in upregulation of p53 in Jun-/- fibroblasts. Rather, Jun was found to negatively regulate transcription of p53 by direct binding to a conserved AP-1 site in the p53 promoter. Furthermore, overexpression of Jun accelerates cell proliferation, whereas the absence of Jun results in a severe proliferation defect and a prolonged crisis prior to spontaneous immortalisation. The cyclin D1- and cyclin E-dependent kinases (CDKs) and transcription factor E2F are poorly activated, resulting in inefficient G1 to S-phase progression. Importantly, deletion of p53 abrogates all defects of Jun-/- cells in cell cycle progression, proliferation, immortalisation, and activation of G1 CDKs and E2F. These results demonstrate that the sole rate-limiting function of Jun in fibroblast proliferation is negative regulation of p53 expression, and establish a mechanistic link between Jun-dependent mitogenic signalling and cell cycle regulation. …
Metadata
Title
Negative regulation of p53 expression is an essential, rate-limiting function of Jun in the control of cell cycle progression
Authors
M Schreiber
F Piu
A Kolbus
A Szabowski
U Möhle-Steinlein
J Tian
M Karin
P Angel
EF Wagner
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr167

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine